Search

Your search keyword '"CALVARUSO, Vincenza"' showing total 576 results

Search Constraints

Start Over You searched for: Author "CALVARUSO, Vincenza" Remove constraint Author: "CALVARUSO, Vincenza"
576 results on '"CALVARUSO, Vincenza"'

Search Results

2. Real-world experience with long-term albumin in patients with cirrhosis and ascites

3. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

4. Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis

5. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

6. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms

7. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

8. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

15. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.

16. Baveno VII – Renewing consensus in portal hypertension

17. SAT-113 Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites

18. OS-096-YI Spleen stiffness measurement by transient elastography at 100 Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver diseasefinal results of a european multicenter study

20. FRI-047-YI Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)

21. THU-101 Non-invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis based on the cholestasis degree

22. LBP-038 Expanding knowledge regarding real-world treatment of patients with primary biliary cholangitis with obeticholic acid from the Italian RECAPITULATE cohort

23. OS-017 Deep learning discriminates autoimmune hepatitis and primary biliary cholangitis

24. THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid

26. Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis.

27. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

28. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

29. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

30. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

31. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

32. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

33. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

34. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

35. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

36. Palliative care in patients with hepatocellular carcinoma: Results from a survey among hepatologists and palliative care physicians.

39. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

40. Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review.

41. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).

42. Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin‐22, interleukin‐6 and interleukin‐1Ra concentrations according to portal hypertension and disease severity

44. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

45. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis

46. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

50. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

Catalog

Books, media, physical & digital resources